Triplet Combination Strategies to Manage Metastatic HSPC
Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.
Genomic Testing Practices in Prostate Cancer
Expert perspectives on optimal genomic testing practices in patients with prostate cancer.
Novel Approaches to Optimizing Management of mHSPC
Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.
Patient Scenario 2: Selecting Therapy for mHSPC
Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.
PSMA-Targeted Therapy for nmCRPC
A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.
AR Inhibitor Selection in Nonmetastatic Castration-Resistant Prostate Cancer
Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.
Patient Scenario 1: nmCRPC Identification and Work-up
Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.
ADT Therapy in Prostate Cancer: Agonists vs Antagonists
Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.
Overview on Androgen Deprivation Therapy in Prostate Cancer
A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.
